EGFR and cancer: Currently, EGFR-specific tyrosine kinase inhibitors (TKIs) and monoclonal antibodies are potent strategies to target EGFR mutant cancers though with acquired resistance, but they did not work well in EGFR-overexpression tumors1,3–5.